There is a number on every supplement label. It tells you how much of an ingredient is in the product. It does not tell you how much of that ingredient reaches your bloodstream, crosses the relevant biological barrier, and arrives at the tissue where it needs to act.
That gap — between the dose on the label and the dose your body actually uses — is bioavailability. And it is the most important variable in supplement efficacy that almost nobody in the industry has a financial incentive to explain clearly.
The supplement market is built on label doses. Products are compared by how many milligrams they contain. Marketing leads with quantity. The implicit assumption — that the number on the label corresponds to the amount your body receives — is almost never true, varies enormously between ingredient forms, and is rarely disclosed in a way that allows meaningful comparison.
Understanding bioavailability doesn't just make you a better supplement buyer. It explains why many people take supplements diligently for months and notice very little — and why switching a single ingredient form can produce results that a doubled dose of the original could not.
What bioavailability actually means
Bioavailability is the proportion of a substance that enters circulation and reaches its site of action. For a supplement taken orally, it encompasses everything that happens between swallowing the pill and the active compound reaching the tissue where it functions: dissolution in the gut, absorption across the intestinal wall, first-pass metabolism in the liver, and transport to the target tissue.
At each stage, losses occur. Some compounds dissolve poorly in the gastrointestinal environment. Some are poorly absorbed across the intestinal wall due to molecular size, charge, or solubility. Some are substantially broken down by the liver before they reach systemic circulation — a process called first-pass metabolism that can eliminate a significant proportion of an oral dose before it does anything useful. Some are absorbed but poorly transported to the specific tissue where they're needed.
The result is that the effective dose — what actually reaches the tissue — can be a small fraction of the label dose. For some ingredient forms, the fraction is very small indeed.
The mineral problem: why cheap forms cost more in the long run
Minerals are where the bioavailability gap is most dramatic and most commercially exploited.
Magnesium oxide is the most common magnesium form in budget supplements. It is inexpensive to produce, has a high elemental magnesium content by weight, and looks impressive on a label. It also has an absorption rate of approximately four percent under normal gastrointestinal conditions, according to research comparing mineral salt bioavailability. The other 96 percent passes through and is excreted — which, incidentally, is why magnesium oxide is also used as a laxative. The dose you're paying for is almost entirely not the dose you're receiving.
Magnesium glycinate — a chelated form where magnesium is bound to the amino acid glycine — is absorbed at significantly higher rates. The glycine acts as a carrier, facilitating transport across the intestinal wall via amino acid transport pathways rather than the mineral ion channels that oxide must compete through. The result is a form that reaches the bloodstream more reliably, reaches the brain more efficiently due to glycine's ability to cross the blood-brain barrier, and produces the neurological effects associated with magnesium supplementation — GABA support, nervous system downregulation, sleep architecture improvement — more consistently.
The difference in price between oxide and glycinate is real. The difference in efficacy is larger. A lower-cost supplement containing magnesium oxide is not a bargain. It is a more expensive way to achieve less.
The pattern repeats across mineral categories. Zinc oxide versus zinc picolinate or zinc bisglycinate. Iron as ferrous sulfate versus iron bisglycinate. Calcium carbonate versus calcium citrate malate. In each case, the more bioavailable form costs more per unit weight and delivers more per milligram absorbed. The label dose comparison is almost meaningless without the form context.
The botanical problem: standardisation and what it actually means
With botanical ingredients — plant extracts like ashwagandha, rhodiola, turmeric, and similar — the bioavailability problem has a different character. The issue is not just absorption. It is also composition: what compounds are actually present in the extract, at what concentrations, and how that has been verified.
A generic ashwagandha capsule contains ashwagandha root powder. KSM-66® is a full-spectrum ashwagandha root extract standardised to a minimum of five percent withanolides — the active compound class responsible for ashwagandha's cortisol-modulating and adaptogenic effects — through a proprietary water-based extraction process without alcohol or chemical solvents. These are not the same product. They are not meaningfully comparable at equivalent doses.
The distinction is standardisation: the process of guaranteeing that a specific proportion of the active compound is present and consistent across batches. Unstandardised botanical extracts vary enormously in active compound content depending on growing conditions, harvest timing, and processing method. A product labelled 500mg of ashwagandha root extract could contain almost any amount of withanolides — or almost none.
Branded, standardised ingredient forms — KSM-66® for ashwagandha, Albion® chelates for minerals, BioPerine® for piperine — exist because they represent a verifiable, consistent composition that generic forms do not. The brand is not marketing. It is a specification. When a study shows that ashwagandha reduces cortisol in people under psychological stress, that study almost certainly used KSM-66® or an equivalent standardised extract — not generic root powder. The research does not automatically transfer to unstandardised forms.
This is why the branded ingredient on a label is meaningful information and why its absence is also meaningful information. A supplement containing 'ashwagandha root extract' with no standardisation disclosure and no branded form reference is making a claim it cannot verify.
The delivery format problem: what gets to the tissue
Even a bioavailable ingredient in a verified form faces one more variable: the delivery format affects how much survives the journey to the target tissue.
Capsules and tablets add a dissolution step — the coating or capsule must break down in the gastrointestinal environment before the contents are available for absorption. Enteric-coated tablets are designed to pass through the stomach and dissolve in the small intestine, which is appropriate for some compounds and counterproductive for others. Compressed tablets can have poor dissolution rates depending on the binder and filler composition.
Powdered supplements dissolved in liquid — the format Moongreens uses — bypass the dissolution step entirely. The ingredient is already in solution when it reaches the stomach, which removes a variable and allows absorption to begin immediately. For water-soluble compounds and mineral chelates, this produces meaningfully faster and more complete absorption compared to the equivalent compressed tablet.
There is also the question of what surrounds the active ingredients. BioPerine® — the trademarked form of piperine derived from black pepper — has been shown in multiple studies to enhance the bioavailability of co-administered nutrients by inhibiting intestinal enzymes and transporters that would otherwise metabolise or limit their absorption. The effect is documented for curcumin, certain B vitamins, CoQ10, and a range of other compounds. Including BioPerine® in a formula is not decoration. It is a deliberate bioavailability enhancement decision that affects the effective dose of every other ingredient in the same formula.
What to look for on a label
The practical application of all of this is relatively straightforward once you know what to look for.
For minerals: look for chelated forms — bisglycinate, glycinate, picolinate, citrate malate — rather than oxides, carbonates, or sulfates. The form name follows the mineral name on the ingredient list.
For botanicals: look for standardisation disclosures (a percentage of the active compound class) and branded extract names. If neither is present, the composition of the extract is unverified.
For the overall formula: look for bioavailability enhancers like BioPerine®, and consider the delivery format. A powder in solution removes the dissolution variable. An enteric-coated tablet introduces it.
For branded ingredients specifically: the research attached to a branded form does not transfer to a generic equivalent at the same dose. If the evidence base for an ingredient is built on studies using KSM-66®, Albion® chelates, or similar, those are the forms the evidence actually supports.
The supplement industry's incentive is to make the label number look impressive. Your incentive is to understand how much of that number actually reaches the tissue it's supposed to. These are not the same thing — and closing that gap is the only meaningful definition of value in supplementation.
The dose on the label is not the dose your body receives. That gap is where most supplements fail.